This is therefore a contrasting of the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation in ImmunoGen Inc. (NASDAQ:IMGN) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoGen Inc.	53.45M	7.58	168.84M	-1.20	0.00
Aerpio Pharmaceuticals Inc.	20.16M	2.00	10.40M	-0.44	0.00

Table 1 highlights ImmunoGen Inc. and Aerpio Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of ImmunoGen Inc. and Aerpio Pharmaceuticals Inc.

	Net Margins	Return on Equity	Return on Assets
ImmunoGen Inc.	-315.88%	-733%	-46.9%
Aerpio Pharmaceuticals Inc.	-51.59%	-22.7%	-18.5%

Liquidity

The Current Ratio of ImmunoGen Inc. is 4.6 while its Quick Ratio stands at 4.6. The Current Ratio of rival Aerpio Pharmaceuticals Inc. is 19.2 and its Quick Ratio is has 19.2. Aerpio Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than ImmunoGen Inc.

Analyst Ratings

ImmunoGen Inc. and Aerpio Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
ImmunoGen Inc.	0	3	3	2.50
Aerpio Pharmaceuticals Inc.	0	0	0	0.00

ImmunoGen Inc.’s upside potential is 87.45% at a $5.08 consensus target price.

Insider and Institutional Ownership

Institutional investors held 84.4% of ImmunoGen Inc. shares and 26.6% of Aerpio Pharmaceuticals Inc. shares. ImmunoGen Inc.’s share held by insiders are 0.9%. Comparatively, 0.8% are Aerpio Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ImmunoGen Inc.	-56.01%	-50.48%	-53.82%	-73.84%	-76.39%	-45.83%
Aerpio Pharmaceuticals Inc.	-2.05%	-17.82%	48.96%	-17.82%	-41.63%	68.24%

For the past year ImmunoGen Inc. has -45.83% weaker performance while Aerpio Pharmaceuticals Inc. has 68.24% stronger performance.

Summary

Aerpio Pharmaceuticals Inc. beats ImmunoGen Inc. on 8 of the 11 factors.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.